Furin Antibody (1C3)
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-26563
Recombinant monoclonal antibody expressed in HEK293F cells
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Recombinant Monoclonal Rabbit IgG Clone # 1C3
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for Furin Antibody (1C3)
Immunogen
A synthesized peptide derived from Human Furin [UniProt P09958]
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG
Scientific Data Images for Furin Antibody (1C3)
Immunohistochemistry: Furin Antibody (1C3) [NBP3-26563] -
Immunohistochemistry: Furin Antibody (1C3) [NBP3-26563] - Image of Furin Antibody (1C3) diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4C overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Western Blot: Furin Antibody (1C3) [NBP3-26563] -
Western Blot: Furin Antibody (1C3) [NBP3-26563] - Positive Western Blot detected in: A549 whole cell lysate, Hela whole cell lysate, A375 whole cell lysate, HT-29 whole cell lysate, HepG2 whole cell lysate, U-87 whole cell lysate.All lanes: Furin Antibody at 1: 1000
Secondary: Goat polyclonal to rabbit IgG at 1/50000 dilution.
Predicted band size: 87 kDa
Observed band size: 87, 72 kDa
Applications for Furin Antibody (1C3)
Application
Recommended Usage
Immunohistochemistry
1:50-1:200
Western Blot
1:500-1:5000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, pH 7.4, 150mM NaCl and 50% glycerol
Preservative
0.02% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20 to -70C. Avoid freeze-thaw cycles.
Background: Furin
Proteolytic cleavage regulates several physiological processes in both health and disease (3). Abnormal activity or mutations in proteases, including furin, is associated with pathologies and diseases including cancer, cardiovascular disorders, diabetes, inflammation, neurological diseases, and autoimmune diseases (3). As mentioned above, furin also acts upon bacterial substrates, including anthrax and Shiga toxin, and many virus families such as Herpes-, Flavi-, and Corona-, leading to host infections. Furthermore, the novel coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) present with a S-spike protein that is cleaved by PCs, including furin, at the S1/S2 cleavage site (5, 6). The cleavage allows the SARS-CoV-2 to then attach to the angiotensin-converting enzyme 2 (ACE2) receptor via the S1 domain and the cellular membrane via the S2 domain (5, 6). Although COVID-19 patients mostly present with respiratory symptoms, a variety of other systems are affected including cardiovascular, gastrointestinal (GI), and the liver (5-7). It is suggested that the S1/furin/ACE2 interaction promotes SARS-CoV-2 infection leading to the harmful symptoms and reactions in patients (5, 6). Cardiovascular disease is a common comorbidity in patients, along with hypertension, myocardial damage, and heart palpitations (Ming). Further evidence of furin being a risk factor for infection is the high levels of furin present in the blood of heart failure patients (5). Similarly, the small bowel may be another interaction site for infection as it is rich in furin and the intestinal enterocytes have many ACE2 receptors (6). Furin is also highly expressed in the liver and hepatocytes and cholangiocytes of the liver present ACE2 receptors (3, 7). Studies have shown that up one-third of COVID-19 patients experience GI symptoms which range from diarrhea and loss of appetite to abdominal cramping and bloody stool (6, 7). Additionally, some patients displayed abnormal liver enzyme levels (7). It has been suggested that a possible therapeutic strategy for treating those infected with SARS-CoV-2 is pharmacologically or immunologically modulating furin or ACE2 binding sites to combat COVID-19 infection (3, 5).
References
1. Thomas, G. (2002). Furin at the cutting edge: from protein traffic to emryogenesis and disease. Nature Rev. Mol. Cell Biol. https://doi.org/10.1038/nrm934
2. Zhou A., Paquet, L., & Mains, R.E. (1995). Structural elements that direct specific processing of different mammalian subtilisin-like prohormone convertases. J Biol Chem. https://doi.org/10.1074/jbc.270.37.21509
3. Braun E., & Sauter, D. (2019). Furin-mediated protein processing in infectious diseases and cancer. Clin Transl Immunology. https://doi:10.1002/cti2.1073
4. Atlas of Genetics and Cytogenetics in Oncology and Haematology, FURIN
5. Ming, Y. & Qiang, L. (2020). Involvement of Spike Protein, Furin, and ACE2 in SARS-CoV-2-Related Cardiovascular Complications. SN Compr. Clin. Med. https://doi.org/10.1007/s42399-020-00400-2
6. Monkemuller, K., Fry, L., & Rickes, S. (2020). COVID-19, coronavirus, SARS-CoV-2 and the small bowel. Rev Esp Enferm Dig. https://doi:10.17235/reed.2020.7137/2020
7. Agarwal, A., Chen, A., Ravindran, N., To, C., & Thuluvath, P.J. (2020). Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. https://doi:10.1016/j.jceh.2020.03.001
Alternate Names
FUR, PACE, PCSK3, SPC1
Gene Symbol
FURIN
Additional Furin Products
Product Documents for Furin Antibody (1C3)
Product Specific Notices for Furin Antibody (1C3)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...